TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00219557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
Study: NCT01218620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO
Study: NCT02408835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO™
Description: Negative pressure wound therapy device for closed surgical wounds.
Study: NCT03549078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity.
Study: NCT01801865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDX/GE Electronics
Study: NCT03068234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo for pirfenidone capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
Study: NCT04524793

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)

Intervention type: OTHER
Group type: OTHER
Intervention: Physical examinations
Description: GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
Study: NCT02323373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid - topical
Description: Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of saline solution administered with anesthesia during 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid - intravenous
Description: Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
Study: NCT01450306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg d-cycloserine, oral, 1 dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Single session graded in vivo exposure therapy, 60-180 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure therapy
Description: Single session graded in vivo exposure therapy, 60-180 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Study: NCT04079647

Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients receive immunotherapy for cancer treatment
Study: NCT01492907

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MeIQx
Description: On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MeIQx
Description: On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
Study: NCT03886610

Intervention type: OTHER
Intervention: Healthy controls
Description: individuals without spinal cord injury

Intervention type: OTHER
Intervention: Subacute SCI patients
Description: individuals with spinal cord injury ≥ 2 weeks

Intervention type: OTHER
Intervention: Chronic SCI patients
Description: individuals with spinal cord injury ≥ 24 months
Study: NCT04261829

Intervention type: PROCEDURE
Intervention: Autologous Fat Transfer
Description: Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
Study: NCT00597610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound 3-D (TRUS)
Description: Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
Study: NCT03268980

Intervention type: OTHER
Intervention: Questionnaire Hospital Staff group
Description: One-page questionnaire with 15 questions about tobacco habits

Intervention type: OTHER
Intervention: Questionnaire students and patients group
Description: One-page questionnaire with 17 questions about tobacco habits

Intervention type: OTHER
Intervention: Questionnaire students and patients group
Description: One-page questionnaire with 17 questions about tobacco habits
Study: NCT03485417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: for oral or depot preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: for oral or depot

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
Study: NCT02921685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Four dose levels will be tested.
Study: NCT02852174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Mindfulness meditation training
Study: NCT02375971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Administered as an intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
Study: NCT00774501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image guidance with general anesthesia and suspended ventilation during treatment delivery
Description: All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery.
Study: NCT03244761

Intervention type: PROCEDURE
Intervention: The modified HFT
Description: The HFT was modified by increasing the expiratory resistance.
Study: NCT03266861

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise oximetry
Description: Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
Study: NCT04565197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot
Study: NCT02174510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg lurasidone
Description: single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03948529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
Study: NCT02598232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,414nm Nd:YAG Laser System
Description: It has high absorption coefficient in water and a short pulse width.
Study: NCT00907543

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative treatment of chemotherapy and radiation
Description: Cisplatin + 5FU with concurrent radiation followed by surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative treatment of chemotherapy and radiation
Description: Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
Study: NCT00449865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: creatine
Description: Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT01622218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Clown
Description: Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
Study: NCT06280911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Date Fruit group
Description: Consumption of Date Fruit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nipple group
Description: Nipple Stimulation
Study: NCT01218620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Given IV
Study: NCT01481948

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food, Fun, & Fitness Internet Program for Girls
Description: This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food, Fun, & Fitness Internet Program for Girls
Description: This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
Study: NCT02555228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
Study: NCT03903120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice.
Study: NCT02975882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Albumin-bound Nanoparticles
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04574076

Intervention type: DRUG
Intervention: Turoctocog alfa pegol (N8-GP)
Description: Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT02555228

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 5mls of water is given at least 30 minutes before the gastroscopy.
Study: NCT03981250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home-based resistance exercise programme
Description: Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
Study: NCT04335123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
Study: NCT01160692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)
Description: Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral intake of matching placebo tablets for 3 months
Study: NCT03105908

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet delivered Acceptance and Commitment therapy
Description: The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control condition
Description: After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
Study: NCT03538730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Reframing
Description: The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
Study: NCT04603872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Targeted CAR T-cells and dasatinib
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Targeted CAR T-cells
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
Study: NCT02175433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion
Study: NCT01047384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture-moxibustion therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular therapy